Please assess the completion status of the following clinical trial:

Trial Title: Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 8 and 13 years of age; diagnosed as having ADHD; otherwise healthy;~Exclusion Criteria:~* significant sensory or neurological limitations, epilepsy, mental retardation, psychosis, or pervasive developmental disorder; medications with known central nervous system effects such as tranquilizers, antidepressants, stimulants (including methylphenidate and amphetamines), sedating antihistamines and some asthma medications and dietary supplements but vitamins

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).